Cancer Clinical Trial
Official title:
Communicating About Sexual Concerns and Dysfunction Effectively (CASCADE) Program
Patients with cancer suffer many devastating side effects; one that is understudied but vital
to quality of life is the effect of cancer and its treatments on patients' sexual functioning
and satisfaction. The long-term goal of this work is to improve the care of patients with
cancer who are experiencing difficulties with sexual function and satisfaction. As a
necessary first step, providers must be skilled in eliciting patients' concerns about sexual
health and addressing them appropriately. However, prior studies have found that (1) oncology
providers are reluctant to discuss sexual issues with their patients, (2) patients report
that needed conversations about their sexual concerns do not occur, and (3) patients want to
discuss sexual health with their provider. Thus, the goal of the present study is to develop
and test a brief intervention to improve oncology provider's skills in addressing patients'
concerns regarding sexual function—the Communicating about Sexual Concerns and Dysfunction
Effectively (CASCADE) Program.
To aid in development of the intervention, focus groups will be held and target 9 distinct
populations of cancer survivors: 1) Breast; 2) Gynecologic; 3) Prostate; 4) males with
gastrointestinal malignancies; 5) females with gastrointestinal malignancies; 6) males with
brain tumors; 7) females with brain tumors; 8) LGBTQ individuals who identify as male; 9)
LGBTQ individuals who identify as female. Maximum accrual for this phase will be 90 patients
for 9 focus groups, or a maximum of 10 patients per group. Groups will last approximately 75
minutes and be audio recorded. Participants will also complete self-report measures which as
about their sexual functioning, emotional wellbeing, physical functioning and utilization of
services offered through the Duke Cancer Institute.
The intervention will then be pilot tested with up to 10 providers to assess feasibility and
acceptability of the protocol. Specifically, the coaching intervention will include two
parts: 1) initial coaching session with one of the study PIs, Dr. Kathryn Pollak; and 2)
follow-up appointment with Dr. Pollak to check in on use of the intervention strategies.
Providers will also complete self-report assessments prior to initiating CASCADE and upon
completion of CASCADE. Clinic staff will let patients know that the clinic is participating
in a research study about how to improve communication between patients and providers and
provide patients of participating providers with an anonymous survey to complete following
their clinic visit. The paper surveys will be given to all patients of the participating
provider being seen in the clinic approximately 5 days prior to the coaching intervention
session and 5 days following the intervention (e.g., second session with Dr. Pollak).
Descriptive statistics (e.g., means, standard deviations) will be used to characterize the
experience of patients participating in focus groups with regard to their sexual functioning,
emotional distress (i.e., symptoms of anxiety and depression), and physical functioning.
Qualitative methods will also be used to analyze the focus groups.
Feasibility of CASCADE will be assessed by examining providers' accrual, attrition, and
adherence. To determine acceptability, providers will be asked how useful the intervention
was, whether the intervention will change their clinical practice, and whether they would
recommend the program to a colleague. Simple t-tests will be used to examine changes in
outcomes of interest (e.g., confidence, barriers, etc.) from pre- to post-intervention. Basic
descriptive statistics (e.g., means, standard deviations) will be used to characterize
patients' experiences during the interaction.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|